Long-term effect of intravitreal triamcinolone in the nonproliferative stage of type II idiopathic parafoveal telangiectasia

Retina

Volumn 28, Issue 2, 2008, Pages 314-319

  Wu, Lihteh ^a,f   Evans, Teodoro ^a   Arévalo, J Fernando ^b   Berrocal, María H ^c   Rodríguez, Francisco J ^d   Hsu, María ^e   Sánchez, Juan G ^b  

^a Instituto de Cirugia Ocular   (Costa Rica)

^b Clínica Oftalmológica Caracas Centro   (Venezuela)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d UNIVERSIDAD DEL ROSARIO   (Colombia)

^e Hospital Calderon Guardia   (Costa Rica)

^f NONE   (Costa Rica)

Author keywords

Juxtafoveolar telangiectasis; Macular edema; Macular telangiectasia; Parafoveal telangiectasis; Perifoveal telangiectasia; Triamcinolone

Indexed keywords

TRIAMCINOLONE; GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LENS IMPLANT; MALE; PHACOEMULSIFICATION; TELANGIECTASIA; TREATMENT OUTCOME; TYPE 2 IDIOPATHIC PARAFOVEAL TELANGIECTASIA; VISUAL ACUITY; CLINICAL TRIAL; FLUORESCENCE ANGIOGRAPHY; INJECTION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETINA BLOOD VESSEL; RETINA DISEASE; RETINA FOVEA; RETROSPECTIVE STUDY; VITREOUS BODY;

AGED; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOVEA CENTRALIS; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETINAL DISEASES; RETINAL VESSELS; RETROSPECTIVE STUDIES; TELANGIECTASIS; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 42449151372     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31814cf03e     Document Type: Article

References (25)

1. Reese AB. Telangiectasis of the retina and Coats' disease. Am J Ophthalmol 1956;42:1-8.
2. Gass JD, Oyakawa RT. Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 1982;100:769-780.
3. Gass JD, Blodi BA. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 1993;100:1536-1546.
4. Yannuzzi LA, Bardal AM, Freund KB, et al. Idiopathic macular telangiectasia. Arch Ophthalmol 2006;124:450-460.
5. Potter MJ, Szabo SM, Chan EY, Morris AH. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 2002;133:149-151.
6. Hershberger VS, Hutchins RK, Laber PW. Photodynamic therapy with verteporfin for subretinal neovascularization secondary to bilateral idiopathic acquired juxtafoveolar telangiectasis. Ophthalmic Surg Lasers Imaging 2003;34:318-320.
7. Potter MJ, Szabo SM, Sarraf D, et al. Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis. Can J Ophthalmol 2006;41:34-37.
8. Smithen LM, Spaide RF. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 2004;138:884-885.
9. Eandi CM, Ober MD, Freund KB, et al. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Retina 2006;26:780-785.
10. Park DW, Schatz H, McDonald HR, Johnson RN. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 1997;104:1838-1846.
11. De Lahitte GD, Cohen SY, Gaudric A. Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am J Ophthalmol 2004;138:892-894.
12. Martinez JA. Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch Ophthalmol 2003;121:1658-1659.
13. Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003;23:113-116.
14. Cakir M, Kapran Z, Basar D, et al. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Eur J Ophthalmol 2006;16:711-717.
15. Wilson CA, Berkowitz BA, Sato Y, et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992;110:1155-1159.
16. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258.
17. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005;24:587-611.
18. Paunescu LA, Ko TH, Duker JS, et al. Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography. Ophthalmology 2006;113:48-57.
19. Green WR, Quigley HA, De la Cruz Z, Cohen B. Parafoveal retinal telangiectasis. Light and electron microscopy studies. Trans Ophthalmol Soc UK 1980;100:162-170.
20. Gass JDM. In: Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment, 4 ed. St Louis: Mosby; 1997.
21. Gupta V, Gupta A, Dogra MR, Agarwal A. Optical coherence tomography in group 2A idiopathic juxtafoveolar telangiectasis. Ophthalmic Surg Lasers Imaging 2005;36:482-486.
22. Gaudric A, Ducos de Lahitte G, Cohen SY, et al. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 2006;124:1410-1419.
23. Trabucchi G, Brancato R, Pierro L, et al. Idiopathic juxtafoveolar retinal telangiectasis and pigment epithelial hyperplasia: an optical coherence tomographic study. Arch Ophthalmol 1999;117:405-406.
24. Narayanan R, Mungcal JK, Kenney MC, et al. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci 2006;47:722-728.
25. Yu SY, Damico FM, Viola F, et al. Retinal toxicity of intravitreal triamcinolone acetonide: a morphological study. Retina 2006;26:531-536.